Genesis Therapeutics has a total of 36 patents, out of which 3 have been granted. Of these 36 patents, more than 91% patents are active. The United States of America is where Genesis Therapeutics has filed the maximum number of patents followed by Taiwan and Argentina. Parallelly, United States of America seems to be the main focused R&D center of Genesis Therapeutics and also USA is the origin country of Genesis Therapeutics.
Genesis Therapeutics was founded in the year 2019. The company develops artificial intelligence-driven drug discovery solutions and leverages machine learning to design novel small-molecule therapeutics for complex diseases. It is a startup operating in the biotechnology and pharmaceutical industry.
Do read about some of the most popular patents of Genesis Therapeutics which have been covered by us in this article and also you can find Genesis Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Genesis Therapeutics patent portfolio.
How many patents does Genesis Therapeutics have?
Genesis Therapeutics has a total of 36 patents globally. These patents belong to 10 unique patent families. Out of 36 patents, 33 patents are active.
How Many Patents did Genesis Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Genesis Therapeutics Applications Filed | Genesis Therapeutics Patents Granted |
| 2025 | 7 | 2 |
| 2024 | 10 | 1 |
| 2023 | 19 | – |
How many Genesis Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Genesis Therapeutics File in Different Countries?
Countries in which Genesis Therapeutics Filed Patents
| Country | Patents |
| United States Of America | 4 |
| Taiwan | 3 |
| Argentina | 3 |
| Israel | 1 |
| Singapore | 1 |
| New Zealand | 1 |
| Colombia | 1 |
| Chile | 1 |
| Costa Rica | 1 |
| Mexico | 1 |
| Dominican Republic | 1 |
| Peru | 1 |
| Canada | 1 |
| South Africa | 1 |
| Australia | 1 |
| Indonesia | 1 |
| Europe (EPO) | 1 |
| Africa | 1 |
| India | 1 |
Where are Research Centers of Genesis Therapeutics Patents Located?
Best Genesis Therapeutics Patent
WO2024081904A1 is the most popular patent in the Genesis Therapeutics portfolio. It has received 4 citations so far from companies like Beigene and Cogent Biosciences Inc.
List of Genesis Therapeutics Patents
| Genesis Therapeutics Patents | Title |
| US12288600B2 | Generative Machine Learning On Textual Queries Relating To Molecules |
| US12230367B2 | Chemical Computation Graphs |
| US12159693B2 | Computational Platform For Generating Molecules |
| US20250061980A1 | Computational Platform For Generating Molecules |
| EP4568948A1 | Compounds For Treating Cancer |
| WO2025144931A1 | Methods For Treating Cancer |
| WO2025128616A1 | Compounds For Treating Cancer |
| WO2024229121A1 | Compounds For Treating Cancer |
| WO2024123801A1 | Compounds For Treating Cancer |
| WO2024081904A1 | Methods For Treating Cancer |
| WO2024081889A1 | 4H-Pyrido[1,2-A]Pyrimidin-4-One Derivatives For Treating Cancer |
| WO2024059010A1 | Compounds For Treating Cancer |
| IN202517035688A | Compounds For Treating Cancer |
| CL202500672A1 | Aminopyrimidine Derivatives, Cdk2 Inhibitors; Pharmaceutical Composition; Use In The Treatment Of Cancer. |
| PE0016922025A1 | Compounds For Cancer Treatment |
| CR20250124A | Compounds For Treating Cancer |
| ID202506248A | Compounds For Treatment Of Cancer |
| IL319513A | Compounds For Treating Cancer |
| SG11202501514WA | Compounds For Treating Cancer |
| DOP2025000057A | Compounds For Cancer Treatment |
| MX2025002817A | Compounds For Treating Cancer |
| CO20250003099A2 | Compounds For Cancer Treatment |
| APP2025016361A0 | Compounds For Treating Cancer |
| AU2023342774A1 | Compounds For Treating Cancer |
| ZA202501249A | Compounds For Treating Cancer |
| AR130771A1 | Methods To Treat Cancer |
| AR130769A1 | 4H-Gyped Derivatives [1,2-A] Pyrimidin-4-Ona For Cancer Treatment |
| AR130463A1 | Compounds For The Treatment Of Cancer |
| TW202426427A | Compounds For Treating Cancer |
| TW202421134A | Methods For Treating Cancer |
| TW202421135A | Methods For Treating Cancer |
| NZ818605A | Compounds For Treating Cancer |
| CA3264256A1 | Compounds For Treating Cancer |
| WO2024151613A1 | Generative Machine Learning On Textual Queries Relating To Molecules |
| WO2024151610A1 | Chemical Computation Graphs |
| WO2024151607A1 | A Computational Platform For Generating Molecules |
What are Genesis Therapeutics key innovation segments?
What Technologies are Covered by Genesis Therapeutics?
The chart below distributes patents filed by Genesis Therapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where Genesis Therapeutics thinks it’s important to protect particular technological inventions.
R&D Focus: How has Genesis Therapeutics search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Genesis Therapeutics?
